In Other Journals

Ann Gregory
Med J Aust 2006; 184 (4): . || doi: 10.5694/j.1326-5377.2006.tb00187.x
Published online: 20 February 2006

Canadian researchers have revived a decades-old concern about whether sulfonylurea drug use can cause adverse cardiac events.1,2 They followed a cohort of 5795 patients with type 2 diabetes over an average of 4.6 years.1 All subjects were only taking one of three types of oral anti-diabetic agent — a first generation sulfonylurea (chlorpropamide or tolbutamide), a more recently developed sulfonylurea (glibenclamide), or metformin. The researchers found that the higher the daily dose of sulfonylurea (especially a first-generation sulfonylurea), the greater the risk of death, including death caused by an acute ischaemic event. This association was not found with metformin.

  • Ann Gregory



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.